Van't Veer LJ - Search Results

1

Mammographic screening detects low-risk tumor biology breast cancers.

Drukker CA, Schmidt MK, Rutgers EJ, Cardoso F, Kerlikowske K, Esserman LJ, van Leeuwen FE, Pijnappel RM, Slaets L, Bogaerts J, Van't Veer LJ. Drukker CA, et al. Breast Cancer Res Treat. 2014 Feb;144(1):103-11. doi: 10.1007/s10549-013-2830-5. Epub 2014 Jan 28. Breast Cancer Res Treat. 2014. PMID: 24469641 Free PMC article. Clinical Trial.

2

A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma.

van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ. van Dijk MA, et al. Cancer Res. 1997 Aug 15;57(16):3478-85. Cancer Res. 1997. PMID: 9270016

3

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.

Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van 't Veer LJ. Ligtenberg MJ, et al. Br J Cancer. 1999 Mar;79(9-10):1475-8. doi: 10.1038/sj.bjc.6690235. Br J Cancer. 1999. PMID: 10188893 Free PMC article.

4

Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells.

Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van' t Veer LJ, Rodenhuis S. Lambrechts AC, et al. Breast Cancer Res Treat. 1999 Aug;56(3):219-31. doi: 10.1023/a:1006261731125. Breast Cancer Res Treat. 1999. PMID: 10573113

5

Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas.

van Dijk MA, Hart AA, van 't Veer LJ. van Dijk MA, et al. Cancer Res. 2000 Feb 1;60(3):530-3. Cancer Res. 2000. PMID: 10676630

6

ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.

Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ. Broeks A, et al. Am J Hum Genet. 2000 Feb;66(2):494-500. doi: 10.1086/302746. Am J Hum Genet. 2000. PMID: 10677309 Free PMC article.

7

Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations.

Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van T Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen FE, van T Veer LJ. Broeks A, et al. Int J Radiat Biol. 2000 May;76(5):693-8. doi: 10.1080/095530000138367. Int J Radiat Biol. 2000. PMID: 10866292

8

Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.

Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G. Hogervorst FB, et al. Cancer Res. 2003 Apr 1;63(7):1449-53. Cancer Res. 2003. PMID: 12670888

9

Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation.

Klaren HM, van't Veer LJ, van Leeuwen FE, Rookus MA. Klaren HM, et al. J Natl Cancer Inst. 2003 Jul 2;95(13):941-7. doi: 10.1093/jnci/95.13.941. J Natl Cancer Inst. 2003. PMID: 12837830 Review. No abstract available.

10

Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.

Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ. Broeks A, et al. Breast Cancer Res Treat. 2004 Jan;83(1):91-3. doi: 10.1023/B:BREA.0000010697.49896.03. Breast Cancer Res Treat. 2004. PMID: 14997059

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

391 results

Search Page